September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Multicenter Evaluation of Pediatric Choroidal Neovascular Membrane: Clinical characteristics and treatment outcomes
Author Affiliations & Notes
  • Bradley Anderson
    Ophthalmology, Beaumont Hospital, Royal Oak, MI, United Kingdom
  • Tapas R Padhi
    University of Michigan, Ann Arbot, Michigan, United States
  • Ashkan Abbey
    Associated Retinal Consultants , Royal Oak, Michigan, United States
  • Yoshihiro Yonekawa
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
    Associated Retinal Consultants , Royal Oak, Michigan, United States
  • Kimberly A Drenser
    Associated Retinal Consultants , Royal Oak, Michigan, United States
  • Antonio Capone, Jr.
    Associated Retinal Consultants , Royal Oak, Michigan, United States
  • Michael Thomas Trese
    Associated Retinal Consultants , Royal Oak, Michigan, United States
  • Cagri G Besirli
    University of Michigan, Ann Arbot, Michigan, United States
  • Footnotes
    Commercial Relationships   Bradley Anderson, None; Tapas Padhi, None; Ashkan Abbey, None; Yoshihiro Yonekawa, None; Kimberly Drenser, Allergan (S), FocusROP (S), Synergetics (C), Thrombogenics (S); Antonio Capone, Jr., Allergan (C), FocusROP (C), Novartis (C), Retinal Solutions (C), Synergetics (C); Michael Trese, None; Cagri Besirli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2136. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Bradley Anderson, Tapas R Padhi, Ashkan Abbey, Yoshihiro Yonekawa, Kimberly A Drenser, Antonio Capone, Jr., Michael Thomas Trese, Cagri G Besirli; Multicenter Evaluation of Pediatric Choroidal Neovascular Membrane: Clinical characteristics and treatment outcomes. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2136.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Multicenter evaluation of the clinical characteristics, treatment modalities and outcomes of pediatric choroidal neovascular membranes (CNVM).

Methods : Retrospective case series of all patients 18 years old or less diagnosed with CNVM. Statistical tests were 2-tailed and significance was defined as P < 0.05. Stata version 9.0 (StataCorp, LP, College Station, TX) was used for statistical analyses.

Results : Forty six eyes of 37 patients (16 Male, 21 Female) with a mean age of 11.1 years were analyzed. CNVM was associated with Best vitelliform macular dystrophy (n=14), idiopathic (n=12), post inflammatory (n=4), coloboma (n=4), optic nerve head drusen (n=3), myopia (n=3), choroidal rupture (n=1), persistent fetal vasculature syndrome (n=1), familial exudative vitreoretinopathy (n=1), and choroidal osteoma (n=1). 75% (n=28) of patients had unilateral disease. Presenting visual acuity ranged from count fingers to 20/25. The most common location was subfoveal (56.5%), followed by peripapillary (30.8%), juxtafoveal (13.0%), and extrafoveal (10.9%) (P < 0.001). Fluorescein angiography showed lesions to be classic (90.9%; P < 0.001) in the majority of cases. Optical coherence tomography (OCT) showed mainly type 2 CNVM (76.1%; P < 0.001).

Initial treatment modalities were anti-vascular endothelial growth factors (VEGF) (n=30; 90.9%) or laser (n=3; 9.1%). Bevacizumab was used predominantly (n=20). Anti-VEGF treatment was used alone (n=25), followed by an alternate anti-VEGF agent (n=3) or in combination with laser (n=1) or PDT (n=2). Nineteen eyes (63.3%) showed regression with anti-VEGF treatment alone with a mean of 2.1 (range 1-10) injections. Recurrences occurred in 7 eyes (21.2%) with an average of 1.1 recurrences per eye. Three of these eyes stabilized with repeat anti-VEGF therapy, while the remainder required photodynamic therapy (PDT), laser or surgery (n=1).

Conclusions : This is the largest reported study on pediatric CNVM. Anti-VEGF therapy was effective with a low recurrence rate.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×